Publicação

Drug targeting of inflammatory bowel diseases by biomolecules

Ver documento

Detalhes bibliográficos
Resumo:Inflammatory bowel disease (IBD) is a group of disabling, destructive and incurable immune-mediated inflammatory diseases comprising Crohn's disease (CD) and ulcerative colitis (UC), disorders that are highly prevalent worldwide and demand a large investment in healthcare. A persistent inflammatory state enables the dysfunction and destruction of healthy tissue, hindering the initiation and endurance of wound healing. Current treatments are ineffective at counteracting disease progression. Further, increased risk of serious side effects, other comorbidities and/or opportunistic infections highlight the need for effective treatment options. Gut microbiota, the key to preserving a healthy state, may, alternatively, increase a patient's susceptibility to IBD onset and development given a relevant bacterial dysbiosis. Hence, the main goal of this review is to showcase the main conventional and emerging therapies for IBD, including microbiota-inspired untargeted and targeted approaches (such as phage therapy) to infection control. Special recognition is given to existing targeted strategies with biologics (via monoclonal antibodies, small molecules and nucleic acids) and stimuli-responsive (pH-, enzyme- and reactive oxygen species-triggered release), polymer-based nanomedicine that is specifically directed towards the regulation of inflammation overload (with some nanosystems additionally functionalized with carbohydrates or peptides directed towards M1-macrophages). The overall goal is to restore gut balance and decrease IBD's societal impact.
Autores principais:Antunes, Joana Isabel Costa
Outros Autores:Seabra, Catarina Leal; Domingues, Joana Margarida; Teixeira, Marta Oliveira; Nunes, Cláudia; Costa-Lima, Sofia Antunes; Homem, Natália Cândido; Reis, Salette; Amorim, M. T. Pessoa de; Felgueiras, Helena Prado
Assunto:Biologics Gut dysbiosis Infection Microbiota Crohn’s disease Ulcerative colitis Treatment Polymeric nanoparticles Engenharia e Tecnologia::Engenharia Médica
Ano:2021
País:Portugal
Tipo de documento:artigo
Tipo de acesso:acesso aberto
Instituição associada:Universidade do Minho
Idioma:inglês
Origem:RepositóriUM - Universidade do Minho
_version_ 1867438251263918080
author Antunes, Joana Isabel Costa
author2 Seabra, Catarina Leal
Domingues, Joana Margarida
Teixeira, Marta Oliveira
Nunes, Cláudia
Costa-Lima, Sofia Antunes
Homem, Natália Cândido
Reis, Salette
Amorim, M. T. Pessoa de
Felgueiras, Helena Prado
author2_role author
author
author
author
author
author
author
author
author
author_facet Antunes, Joana Isabel Costa
Seabra, Catarina Leal
Domingues, Joana Margarida
Teixeira, Marta Oliveira
Nunes, Cláudia
Costa-Lima, Sofia Antunes
Homem, Natália Cândido
Reis, Salette
Amorim, M. T. Pessoa de
Felgueiras, Helena Prado
author_role author
contributor_name_str_mv RepositóriUM - Universidade do Minho
country_str PT
creators_json_txt [{\"Person.name\":\"Antunes, Joana Isabel Costa\"},{\"Person.name\":\"Seabra, Catarina Leal\"},{\"Person.name\":\"Domingues, Joana Margarida\"},{\"Person.name\":\"Teixeira, Marta Oliveira\"},{\"Person.name\":\"Nunes, Cláudia\"},{\"Person.name\":\"Costa-Lima, Sofia Antunes\"},{\"Person.name\":\"Homem, Natália Cândido\"},{\"Person.name\":\"Reis, Salette\"},{\"Person.name\":\"Amorim, M. T. Pessoa de\"},{\"Person.name\":\"Felgueiras, Helena Prado\"}]
datacite.contributors.contributor.contributorName.fl_str_mv RepositóriUM - Universidade do Minho
datacite.creators.creator.creatorName.fl_str_mv Antunes, Joana Isabel Costa
Seabra, Catarina Leal
Domingues, Joana Margarida
Teixeira, Marta Oliveira
Nunes, Cláudia
Costa-Lima, Sofia Antunes
Homem, Natália Cândido
Reis, Salette
Amorim, M. T. Pessoa de
Felgueiras, Helena Prado
datacite.date.Accepted.fl_str_mv 2021-08-01T00:00:00Z
datacite.date.available.fl_str_mv 2021-09-27T09:44:54Z
datacite.date.embargoed.fl_str_mv 2021-09-27T09:44:54Z
datacite.rights.fl_str_mv http://purl.org/coar/access_right/c_abf2
datacite.subjects.subject.fl_str_mv Biologics
Gut dysbiosis
Infection
Microbiota
Crohn’s disease
Ulcerative colitis
Treatment
Polymeric nanoparticles
Engenharia e Tecnologia::Engenharia Médica
datacite.titles.title.fl_str_mv Drug targeting of inflammatory bowel diseases by biomolecules
dc.contributor.none.fl_str_mv RepositóriUM - Universidade do Minho
dc.creator.none.fl_str_mv Antunes, Joana Isabel Costa
Seabra, Catarina Leal
Domingues, Joana Margarida
Teixeira, Marta Oliveira
Nunes, Cláudia
Costa-Lima, Sofia Antunes
Homem, Natália Cândido
Reis, Salette
Amorim, M. T. Pessoa de
Felgueiras, Helena Prado
dc.date.Accepted.fl_str_mv 2021-08-01T00:00:00Z
dc.date.available.fl_str_mv 2021-09-27T09:44:54Z
dc.date.embargoed.fl_str_mv 2021-09-27T09:44:54Z
dc.format.none.fl_str_mv application/pdf
dc.identifier.none.fl_str_mv https://hdl.handle.net/1822/74156
dc.language.none.fl_str_mv eng
dc.publisher.none.fl_str_mv MDPI
dc.rights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.subject.none.fl_str_mv Biologics
Gut dysbiosis
Infection
Microbiota
Crohn’s disease
Ulcerative colitis
Treatment
Polymeric nanoparticles
Engenharia e Tecnologia::Engenharia Médica
dc.title.fl_str_mv Drug targeting of inflammatory bowel diseases by biomolecules
dc.type.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
description Inflammatory bowel disease (IBD) is a group of disabling, destructive and incurable immune-mediated inflammatory diseases comprising Crohn's disease (CD) and ulcerative colitis (UC), disorders that are highly prevalent worldwide and demand a large investment in healthcare. A persistent inflammatory state enables the dysfunction and destruction of healthy tissue, hindering the initiation and endurance of wound healing. Current treatments are ineffective at counteracting disease progression. Further, increased risk of serious side effects, other comorbidities and/or opportunistic infections highlight the need for effective treatment options. Gut microbiota, the key to preserving a healthy state, may, alternatively, increase a patient's susceptibility to IBD onset and development given a relevant bacterial dysbiosis. Hence, the main goal of this review is to showcase the main conventional and emerging therapies for IBD, including microbiota-inspired untargeted and targeted approaches (such as phage therapy) to infection control. Special recognition is given to existing targeted strategies with biologics (via monoclonal antibodies, small molecules and nucleic acids) and stimuli-responsive (pH-, enzyme- and reactive oxygen species-triggered release), polymer-based nanomedicine that is specifically directed towards the regulation of inflammation overload (with some nanosystems additionally functionalized with carbohydrates or peptides directed towards M1-macrophages). The overall goal is to restore gut balance and decrease IBD's societal impact.
dirty 0
eu_rights_str_mv openAccess
format article
fulltext.url.fl_str_mv https://repositorium.uminho.pt/bitstreams/231fdaa5-6cec-4edc-98b6-0067eb96553b/download
id rum_4901adbedf17c9692ef4dcd034378b9e
identifier.url.fl_str_mv https://hdl.handle.net/1822/74156
instacron_str repositorium
institution Universidade do Minho
instname_str Universidade do Minho
language eng
network_acronym_str rum
network_name_str RepositóriUM - Universidade do Minho
oai_identifier_str oai:repositorium.uminho.pt:1822/74156
organization_str_mv urn:organizationAcronym:repositorium
person_str_mv Antunes, Joana Isabel Costa
Seabra, Catarina Leal
Domingues, Joana Margarida
Teixeira, Marta Oliveira
Nunes, Cláudia
Costa-Lima, Sofia Antunes
Homem, Natália Cândido
Reis, Salette
Amorim, M. T. Pessoa de
Felgueiras, Helena Prado
publishDate 2021
publisher.none.fl_str_mv MDPI
reponame_str RepositóriUM - Universidade do Minho
repository_id_str urn:repositoryAcronym:rum
service_str_mv urn:repositoryAcronym:rum
spelling engMDPIporInflammatory bowel disease (IBD) is a group of disabling, destructive and incurable immune-mediated inflammatory diseases comprising Crohn's disease (CD) and ulcerative colitis (UC), disorders that are highly prevalent worldwide and demand a large investment in healthcare. A persistent inflammatory state enables the dysfunction and destruction of healthy tissue, hindering the initiation and endurance of wound healing. Current treatments are ineffective at counteracting disease progression. Further, increased risk of serious side effects, other comorbidities and/or opportunistic infections highlight the need for effective treatment options. Gut microbiota, the key to preserving a healthy state, may, alternatively, increase a patient's susceptibility to IBD onset and development given a relevant bacterial dysbiosis. Hence, the main goal of this review is to showcase the main conventional and emerging therapies for IBD, including microbiota-inspired untargeted and targeted approaches (such as phage therapy) to infection control. Special recognition is given to existing targeted strategies with biologics (via monoclonal antibodies, small molecules and nucleic acids) and stimuli-responsive (pH-, enzyme- and reactive oxygen species-triggered release), polymer-based nanomedicine that is specifically directed towards the regulation of inflammation overload (with some nanosystems additionally functionalized with carbohydrates or peptides directed towards M1-macrophages). The overall goal is to restore gut balance and decrease IBD's societal impact.application/pdfporDrug targeting of inflammatory bowel diseases by biomoleculesAntunes, Joana Isabel CostaSeabra, Catarina LealDomingues, Joana MargaridaTeixeira, Marta OliveiraNunes, CláudiaCosta-Lima, Sofia AntunesHomem, Natália CândidoReis, SaletteAmorim, M. T. Pessoa deFelgueiras, Helena PradoHostingInstitutionOrganizationalRepositóriUM - Universidade do Minhoe-mailmailto:repositorium@usdb.uminho.ptrepositorium@usdb.uminho.ptCITATIONAntunes, J. C., Seabra, C. L., Domingues, J. M., Teixeira, M. O., Nunes, C., Costa-Lima, S. A., ... & Felgueiras, H. P. (2021). Drug Targeting of Inflammatory Bowel Diseases by Biomolecules. Nanomaterials, 11(8), 2035ISSNIsPartOf2079-4991DOIIsPartOf10.3390/nano110820352021-09-27T09:44:54Z2021-082021-062021-08-01T00:00:00ZHandlehttps://hdl.handle.net/1822/74156http://purl.org/coar/access_right/c_abf2open accessBiologicsGut dysbiosisInfectionMicrobiotaCrohn’s diseaseUlcerative colitisTreatmentPolymeric nanoparticleshttp://www.oecd.org/science/inno/38235147.pdfFields of Science and Technology (FOS)Engenharia e Tecnologia::Engenharia Médica1504919 bytesliteraturehttp://purl.org/coar/resource_type/c_6501journal articlehttp://purl.org/coar/access_right/c_abf2application/pdffulltexthttps://repositorium.uminho.pt/bitstreams/231fdaa5-6cec-4edc-98b6-0067eb96553b/download
spellingShingle Drug targeting of inflammatory bowel diseases by biomolecules
Antunes, Joana Isabel Costa
Biologics
Gut dysbiosis
Infection
Microbiota
Crohn’s disease
Ulcerative colitis
Treatment
Polymeric nanoparticles
Engenharia e Tecnologia::Engenharia Médica
status SINGLETON
subject.fl_str_mv Biologics
Gut dysbiosis
Infection
Microbiota
Crohn’s disease
Ulcerative colitis
Treatment
Polymeric nanoparticles
subject.other.fl_str_mv Engenharia e Tecnologia::Engenharia Médica
title Drug targeting of inflammatory bowel diseases by biomolecules
title_full Drug targeting of inflammatory bowel diseases by biomolecules
title_fullStr Drug targeting of inflammatory bowel diseases by biomolecules
title_full_unstemmed Drug targeting of inflammatory bowel diseases by biomolecules
title_short Drug targeting of inflammatory bowel diseases by biomolecules
title_sort Drug targeting of inflammatory bowel diseases by biomolecules
topic Biologics
Gut dysbiosis
Infection
Microbiota
Crohn’s disease
Ulcerative colitis
Treatment
Polymeric nanoparticles
Engenharia e Tecnologia::Engenharia Médica
topic_facet Biologics
Gut dysbiosis
Infection
Microbiota
Crohn’s disease
Ulcerative colitis
Treatment
Polymeric nanoparticles
Engenharia e Tecnologia::Engenharia Médica
url https://hdl.handle.net/1822/74156
visible 1